C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) G01N 33/50 (2006.01)
Patent
CA 2703026
The present invention relates to the use of ecteinascidin 743 in human patients having' certain molecular mark-ers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG (ERCC5) mRNA or protein and/or having a "wild type" genotype for Asp11O4His SNP of XPG gene.
La présente invention concerne l'utilisation de l'ectéinascidine 743 chez des patients humains qui présentent un certain profil de marqueurs moléculaires qui a été associé au résultat de la chimiothérapie par ET-743. L'invention concerne notamment l'utilisation de l'ectéinascidine 743 chez des patients qui présentent des niveaux d'expression élevés de protéine ou d'ARNm XPG (ERCC5) et/ou qui présentent un génotype = de type sauvage = pour AspllO4His SNP du gène XPG.
Costa Rafael Rosell
Diez Rodriguez Ana
Jimeno Donaque Jose Mo
Martinez Magunacelaya Nerea
Taron Roca Miguel
Perry + Currier
Pharma Mar S.a.
LandOfFree
Prognostic molecular markers for et-743 treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prognostic molecular markers for et-743 treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prognostic molecular markers for et-743 treatment will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2024530